Abstract
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disease characterized by intestinal inflammation and epithelial injury. For the treatment of IBD, 5-aminosalicylic acids, corticosteroids, immunomodulators, and biologic agents targeting tumor necrosis factor (TNF)-α, α4β7-integrin, and interleukin (IL)-12/23 have been widely used. Especially, anti-TNF-α antibodies are the first biologic agents that presently remain at the forefront. However, 10–30% of patients resist biologic agents, including anti-TNF-α agents (primary non-responder; PNR), and 20–50% of primary responders develop treatment resistance within one year (secondary loss of response; SLR). Nonetheless, the etiologies of PNR and SLR are not clearly understood, and predictors of response to biologic agents are also not defined yet. Numerous studies are being performed to discover prediction markers of the response to biologic agents, and this review will introduce currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P (2019) Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology 157:1279-1292.e1211. https://doi.org/10.1053/j.gastro.2019.07.025
Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V (2020) Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease. BioDrugs 34:713–721. https://doi.org/10.1007/s40259-020-00451-w
Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:205–217. https://doi.org/10.1038/nrgastro.2015.34
Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajor A, Hjortswang H, Hammarlund P, Grip O, Torp J, Marsal J, Hertervig E (2017) Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther 45:519–532. https://doi.org/10.1111/apt.13893
Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S (2020) Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther 20:413–420. https://doi.org/10.1080/14712598.2020.1732919
Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, Matsumoto T, Matsui T, Kakuta Y, Kinouchi Y, Shimosegawa T, Hosokawa M, Arimura Y, Shinomura Y, Kiyohara Y, Tsunoda T, Kamatani N, Iida M, Nakamura Y, Kubo M (2009) A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet 41:1325–1329. https://doi.org/10.1038/ng.482
Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20:313–318. https://doi.org/10.1038/nm.3462
Baird AC, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott SL, Lawrance IC, Tulic MK (2016) Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol 22:9104–9116. https://doi.org/10.3748/wjg.v22.i41.9104
Barberio B, Dincà R, Facchin S, Dalla Gasperina M, Fohom Tagne CA, Cardin R, Ghisa M, Lorenzon G, Marinelli C, Savarino EV, Zingone F (2020) Matrix metalloproteinase 3 predicts therapeutic response in inflammatory bowel disease patients treated with infliximab. Inflamm Bowel Dis 26:756–763. https://doi.org/10.1093/ibd/izz195
Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, Andersen V (2016) Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther 44:554–567. https://doi.org/10.1111/apt.13736
Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, Macdonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N (2019) IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 129:1910–1925. https://doi.org/10.1172/JCI121668
Beltrán B, Iborra M, Sáez-González E, Marqués-Miñana MR, Moret I, Cerrillo E, Tortosa L, Bastida G, Hinojosa J, Poveda-Andrés JL, Nos P (2019) Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn’s disease. Dig Dis 37:108–115. https://doi.org/10.1159/000492626
Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, Van Langenberg DR (2018) Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohns Colitis 12:289–297. https://doi.org/10.1093/ecco-jcc/jjx146
Blaho VA, Hla T (2014) An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 55:1596–1608. https://doi.org/10.1194/jlr.R046300
Bogaert S, Laukens D, Peeters H, Melis L, Olievier K, Boon N, Verbruggen G, Vandesompele J, Elewaut D, De Vos M (2010) Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol 11:61. https://doi.org/10.1186/1471-2172-11-61
Bosca-Watts MM, Tosca J, Anton R, Mora M, Minguez M, Mora F (2015) Pathogenesis of Crohn’s disease: bug or no bug. World J Gastrointest Pathophysiol 6:1–12. https://doi.org/10.4291/wjgp.v6.i1.1
Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K (2001) Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology 121:1428–1436. https://doi.org/10.1053/gast.2001.29568
Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S (2020) Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 52:1453–1468. https://doi.org/10.1111/apt.16096
Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M (2016) Distinct anti-IFI16 and anti-GP2 antibodies in inflammatory bowel disease and their variation with infliximab therapy. Inflamm Bowel Dis 22:2977–2987. https://doi.org/10.1097/MIB.0000000000000926
Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB (1994) Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372:190–193. https://doi.org/10.1038/372190a0
Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV Jr (2015) Efficacy and safety of natalizumab and vedolizumab for the management of Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis 21:1695–1708. https://doi.org/10.1097/MIB.0000000000000373
Chang JT (2020) Pathophysiology of inflammatory bowel diseases. N Engl J Med 383:2652–2664. https://doi.org/10.1056/NEJMra2002697
Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH, Diseases ISGotKAftSotI (2016) Efficacy and safety of infliximab therapy and predictors of response in korean patients with Crohn’s disease: a nationwide, multicenter study. Yonsei Med J 57:1376–1385. https://doi.org/10.3349/ymj.2016.57.6.1376
Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT (2015) Laboratory markers in ulcerative colitis: current insights and future advances. World J Gastrointest Pathophysiol 6:13–22. https://doi.org/10.4291/wjgp.v6.i1.13
D’amico F, Peyrin-Biroulet L, Danese S (2020a) JAK or GUT selectivity: tipping the balance for efficacy and safety in ulcerative colitis. J Crohns Colitis 14:1185–1187. https://doi.org/10.1093/ecco-jcc/jjaa074
D’amico F, Peyrin-Biroulet L, Danese S, Fiorino G (2020b) New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 55:141–150. https://doi.org/10.1016/j.coph.2020.10.015
Danese S, Sans M, Fiocchi C (2004) Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 3:394–400. https://doi.org/10.1016/j.autrev.2004.03.002
Danese S, Grisham M, Hodge J, Telliez JB (2016) JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 310:G155-162. https://doi.org/10.1152/ajpgi.00311.2015
De Vries LCS, Ghiboub M, Van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D’haens Wildenberg De Jonge GRMEWJ (2020) Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjaa199
Dige A, Stoy S, Rasmussen TK, Kelsen J, Hvas CL, Sandahl TD, Dahlerup JF, Deleuran B, Agnholt J (2013) Increased levels of circulating Th17 cells in quiescent versus active Crohn’s disease. J Crohns Colitis 7:248–255. https://doi.org/10.1016/j.crohns.2012.06.015
Ding NS, Hart A, De Cruz P (2016) Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease—algorithm for practical management. Aliment Pharmacol Ther 43:30–51. https://doi.org/10.1111/apt.13445
Ding NS, Mcdonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL (2020) Metabonomics and the gut microbiome associated with primary response to Anti-TNF therapy in Crohn’s disease. J Crohns Colitis 14:1090–1102. https://doi.org/10.1093/ecco-jcc/jjaa039
Dogra S, Khullar G (2013) Tumor necrosis factor-alpha antagonists: side effects and their management. Indian J Dermatol Venereol Leprol 79(Suppl 7):S35-46. https://doi.org/10.4103/0378-6323.115526
Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD (2018) Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn’s disease patients. mBio 9:17. https://doi.org/10.1128/mBio.02120-17
Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, Ben Yehoyada M, Mould DR (2014) Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 20:2247–2259. https://doi.org/10.1097/MIB.0000000000000212
Dubois-Camacho K, Ottum PA, Franco-Munoz D, De La Fuente M, Torres-Riquelme A, Diaz-Jimenez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA (2017) Glucocorticosteroid therapy in inflammatory bowel diseases: from clinical practice to molecular biology. World J Gastroenterol 23:6628–6638. https://doi.org/10.3748/wjg.v23.i36.6628
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C (2018) Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease. Gastroenterology 155:687-695.e610. https://doi.org/10.1053/j.gastro.2018.05.039
Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F, Getaid Observ-Ibd VICTCC (2020a) A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease. Aliment Pharmacol Ther 51:553–564. https://doi.org/10.1111/apt.15609
Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C (2020b) Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis. Clin Gastroenterol Hepatol 18:2952-2961.e2958. https://doi.org/10.1016/j.cgh.2020.02.010
Fakhoury M, Negrulj R, Mooranian A, Al-Salami H (2014) Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 7:113–120. https://doi.org/10.2147/JIR.S65979
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260. https://doi.org/10.1053/gast.2001.26279
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, De Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, Group U-I-US (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960. https://doi.org/10.1056/NEJMoa1602773
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D’haens G (2020) Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 5:819–828. https://doi.org/10.1016/S2468-1253(20)30188-6
Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949–1954. https://doi.org/10.1111/j.1572-0241.2000.02262.x
Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P (2007) Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13:123–128. https://doi.org/10.1002/ibd.20054
Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D’hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P (2008) Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2:219–225. https://doi.org/10.1016/j.crohns.2008.03.004
Fine S, Papamichael K, Cheifetz AS (2019) Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol 15:656–665
Galgut BJ, Lemberg DA, Day AS, Leach ST (2017) The value of fecal markers in predicting relapse in inflammatory bowel diseases. Front Pediatr 5:292. https://doi.org/10.3389/fped.2017.00292
Gaya DR, Russell RK, Nimmo ER, Satsangi J (2006) New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367:1271–1284. https://doi.org/10.1016/S0140-6736(06)68345-1
Ghoreschi K, Laurence A, O’shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273–287. https://doi.org/10.1111/j.1600-065X.2008.00754.x
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE (2019) Ustekinumab safety in psoriasis, psoriatic arthritis, and crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf 42:751–768. https://doi.org/10.1007/s40264-019-00797-3
Gisbert JP, Gomollon F (2008) Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103:1783–1800. https://doi.org/10.1111/j.1572-0241.2008.01848.x
Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14:694–709. https://doi.org/10.1093/ecco-jcc/jjz195
Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR, On Behalf of the Swiss Ibdnet aowgotSSoG (2020) Therapeutic drug monitoring to guide clinical decision making in inflammatory bowel disease patients with loss of response to anti-TNF: a delphi technique-based consensus. Digestion 101:683–691. https://doi.org/10.1159/000501930
Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I (2017) Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol 23:238–245. https://doi.org/10.4103/sjg.SJG_599_16
Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, Van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S (2005) Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther 22:613–626. https://doi.org/10.1111/j.1365-2036.2005.02635.x
Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S (2007) Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis 13:372–379. https://doi.org/10.1002/ibd.20024
Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, Arnott ID, Satsangi J (2009) Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 104:673–678. https://doi.org/10.1038/ajg.2008.119
Hovde O, Moum BA (2012) Epidemiology and clinical course of Crohn’s disease: results from observational studies. World J Gastroenterol 18:1723–1731. https://doi.org/10.3748/wjg.v18.i15.1723
Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE, Cortot A, Colombel JF, Thomas G (1996) Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379:821–823. https://doi.org/10.1038/379821a0
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603. https://doi.org/10.1038/35079107
Iacucci M, De Silva S, Ghosh S (2010) Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol 24:127–133. https://doi.org/10.1155/2010/586092
Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, Van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P, (Geteccu). SWGoCsDaUC (2017) Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol 52:788–799. https://doi.org/10.1007/s00535-016-1274-1
Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE Jr, Murphy KM (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181:1755–1762. https://doi.org/10.1084/jem.181.5.1755
Jairath V, Khanna R, Feagan BG (2017) Alicaforsen for the treatment of inflammatory bowel disease. Expert Opin Investig Drugs 26:991–997. https://doi.org/10.1080/13543784.2017.1349753
Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, Kühl AA, Glauben R, Lissner D, Siegmund B (2020) Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2020.03.066
Johnson GJ, Cosnes J, Mansfield JC (2005) Review article: smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther 21:921–931. https://doi.org/10.1111/j.1365-2036.2005.02424.x
Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts P, Reinisch W (2006) Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 55:1667–1669. https://doi.org/10.1136/gut.2005.089623
Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S (2011) Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60:631–637. https://doi.org/10.1136/gut.2010.223263
Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR (2004) Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 53:1479–1484. https://doi.org/10.1136/gut.2003.024828
Juyal G, Negi S, Sood A, Gupta A, Prasad P, Senapati S, Zaneveld J, Singh S, Midha V, Van Sommeren S, Weersma RK, Ott J, Jain S, Juyal RC, Thelma BK (2015) Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis. Gut 64:571–579. https://doi.org/10.1136/gutjnl-2013-306625
Kakuta Y, Kawai Y, Naito T, Hirano A, Umeno J, Fuyuno Y, Liu Z, Li D, Nakano T, Izumiyama Y, Ichikawa R, Okamoto D, Nagai H, Matsumoto S, Yamamoto K, Yokoyama N, Chiba H, Shimoyama Y, Onodera M, Moroi R, Kuroha M, Kanazawa Y, Kimura T, Shiga H, Endo K, Negoro K, Yasuda J, Esaki M, Tokunaga K, Nakamura M, Matsumoto T, Mcgovern DPB, Nagasaki M, Kinouchi Y, Shimosegawa T, Masamune A (2019) A genome-wide association study identifying RAP1A as a novel susceptibility gene for Crohn’s disease in Japanese individuals. J Crohns Colitis 13:648–658. https://doi.org/10.1093/ecco-jcc/jjy197
Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS (2019) Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol 206:9–14. https://doi.org/10.1016/j.clim.2018.03.004
Kemp R, Dunn E, Schultz M (2013) Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 27:585–590. https://doi.org/10.1007/s40259-013-0045-2
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, Mcdonald TJ, Mcgovern D, Goodhand JR, Ahmad T, Group UKIBDPS (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4:341–353. https://doi.org/10.1016/S2468-1253(19)30012-3
Kevans D, Waterman M, Milgrom R, Xu W, Van Assche G, Silverberg M (2015) Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis. J Gastroenterol Hepatol 30:64–70. https://doi.org/10.1111/jgh.12661
Klein A, Eliakim R (2010) Non steroidal anti-inflammatory drugs and inflammatory bowel disease. Pharmaceuticals 3:1084–1092. https://doi.org/10.3390/ph3041084
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T (2020) Ulcerative colitis. Nat Rev Dis Primers 6:74. https://doi.org/10.1038/s41572-020-0205-x
Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A, De Vos WM (2015) Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol 110:921–930. https://doi.org/10.1038/ajg.2015.149
Kopylov U, Ben-Horin S, Seidman E (2014) Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol 27:304–312
Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P (2013) Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol 69:431–438. https://doi.org/10.1007/s00228-012-1389-0
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:s1–s106. https://doi.org/10.1136/gutjnl-2019-318484
Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO, Lee SH, Jang BI, Kim JW, Park YS, Kim ES, Choi CH, Kim HJ, IBD study Group of Korean Association for the Study of Intestinal Diseases (2013) Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol 28:1829–1833. https://doi.org/10.1111/jgh.12324
Li P, Zheng Y, Chen X (2017) Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460. https://doi.org/10.3389/fphar.2017.00460
Macaluso FS, Orlando A, Cottone M (2019) Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther 19:89–98. https://doi.org/10.1080/14712598.2019.1561850
Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63:1275–1283. https://doi.org/10.1136/gutjnl-2013-304833
Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung KA, Øhman L (2016) Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 10:943–952. https://doi.org/10.1093/ecco-jcc/jjw051
Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, Yamauchi R, Fukunaga S, Torimura T (2016) Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol 22:1304–1310. https://doi.org/10.3748/wjg.v22.i3.1304
Miyoshi J, Hisamatsu T, Matsuoka K, Naganuma M, Maruyama Y, Yoneno K, Mori K, Kiyohara H, Nanki K, Okamoto S, Yajima T, Iwao Y, Ogata H, Hibi T, Kanai T (2014) Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn’s disease. Digestion 90:130–136. https://doi.org/10.1159/000365783
Morita Y, Bamba S, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A (2016) Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis. Scand J Gastroenterol 51:934–941. https://doi.org/10.3109/00365521.2016.1144781
Motaghi E, Ghasemi-Pirbaluti M, Zabihi M (2019) Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison. Pharmacol Res 139:120–125. https://doi.org/10.1016/j.phrs.2018.11.003
Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P (2016) The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn’s disease. Aliment Pharmacol Ther 44:170–180. https://doi.org/10.1111/apt.13671
Neurath M (2010) Thiopurines in IBD: what is their mechanism of action? Gastroenterol Hepatol 6:435–436
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0
Nguyen DL, Nguyen ET, Bechtold ML (2015) pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. South Med J 108:139–143. https://doi.org/10.14423/SMJ.0000000000000253
Nielsen OH, Ainsworth MA (2013) Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369:754–762. https://doi.org/10.1056/NEJMct1209614
Nielsen OH, Vainer B, Rask-Madsen J (2001) Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 15:1699–1708. https://doi.org/10.1046/j.1365-2036.2001.01102.x
Nielsen OH, Bjerrum JT, Herfarth H, Rogler G (2013) Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol 53:575–588. https://doi.org/10.1002/jcph.2
Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M (2017) Sphingosine-1-phosphate signaling in inflammatory bowel disease. Trends Mol Med 23:362–374. https://doi.org/10.1016/j.molmed.2017.02.002
Nielsen OH, Ainsworth MA, Steenholdt C (2019) Methotrexate for inflammatory bowel disease: time for reconsideration. Expert Rev Gastroenterol Hepatol 13:407–409. https://doi.org/10.1080/17474124.2019.1596797
Nielsen OH, Steenholdt C, Juhl CB, Rogler G (2020) Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 20:100271. https://doi.org/10.1016/j.eclinm.2020.100271
Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y (2017) Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis. PLoS ONE 12:e0169845. https://doi.org/10.1371/journal.pone.0169845
Nunes T, Etchevers MJ, Domènech E, García-Sánchez V, Ber Y, Peñalva M, Merino O, Nos P, Garcia-Planella E, Casbas AG, Esteve M, Taxonera Samsó C, Montoro Huguet M, Gisbert JP, Martín Arranz MD, García-Sepulcre MF, Barreiro-De Acosta M, Beltrán B, Alcaide Suárez N, Saro Gismera C, Cabriada JL, Cañas-Ventura A, Gomollón F, Panés J, Geteccu T-ESGo (2013) Smoking does influence disease behaviour and impacts the need for therapy in Crohn’s disease in the biologic era. Aliment Pharmacol Ther 38:752–760. https://doi.org/10.1111/apt.12440
Nurbhai S, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, Reckless J, Mohammed H, Irving P, Macdonald TT, Vossenkamper A, West MR, Parkes GC, Crowe JS (2019) Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients. Sci Rep 9:14042. https://doi.org/10.1038/s41598-019-50545-x
Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH (2016) Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther 159:110–119. https://doi.org/10.1016/j.pharmthera.2016.01.001
Olivera P, Danese S, Peyrin-Biroulet L (2017) JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol 13:693–703. https://doi.org/10.1080/1744666X.2017.1291342
Olsen T, Goll R, Cui G, Christiansen I, Florholmen J (2009) TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 46:222–227. https://doi.org/10.1016/j.cyto.2009.02.001
Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourié B, Hebuterne X, Bigard MA, Peyrin-Biroulet L (2010) A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 105:2617–2625. https://doi.org/10.1038/ajg.2010.345
Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E (2017) Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66:1049–1059. https://doi.org/10.1136/gutjnl-2016-312735
Park SC, Jeen YT (2019) Genetic studies of inflammatory bowel disease-focusing on Asian patients. Cells 8:404. https://doi.org/10.3390/cells8050404
Pelczar P, Witkowski M, Perez LG, Kempski J, Hammel AG, Brockmann L, Kleinschmidt D, Wende S, Haueis C, Bedke T, Krasemann S, Steurer S, Booth CJ, Busch P, König A, Rauch U, Benten D, Izbicki JR, Rösch T, Lohse AW, Strowig T, Gagliani N, Flavell RA, Huber S (2016) A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science 354:358–362. https://doi.org/10.1126/science.aah5903
Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P, Clementi E (2015) Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract 2015:456895. https://doi.org/10.1155/2015/456895
Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (2017) Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev 16:495–503. https://doi.org/10.1016/j.autrev.2017.03.007
Pithadia AB, Jain S (2011) Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 63:629–642. https://doi.org/10.1016/s1734-1140(11)70575-8
Ponder A, Long MD (2013) A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 5:237–247. https://doi.org/10.2147/CLEP.S33961
Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P (2014) Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis 20:978–986. https://doi.org/10.1097/MIB.0000000000000036
Ramamoorthy S, Cidlowski JA (2016) Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am 42(15–31):vii. https://doi.org/10.1016/j.rdc.2015.08.002
Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP (2006) Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 101:2410–2422. https://doi.org/10.1111/j.1572-0241.2006.00840.x
Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T (1997) Pre-illness dietary factors in inflammatory bowel disease. Gut 40:754–760. https://doi.org/10.1136/gut.40.6.754
Riordan AM, Ruxton CH, Hunter JO (1998) A review of associations between Crohn’s disease and consumption of sugars. Eur J Clin Nutr 52:229–238. https://doi.org/10.1038/sj.ejcn.1600556
Roda G, Jharap B, Neeraj N, Colombel JF (2016) Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 7:e135. https://doi.org/10.1038/ctg.2015.63
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S (2020) Crohn’s disease. Nat Rev Dis Primers 6:22. https://doi.org/10.1038/s41572-020-0156-2
Rusnak F, Mertz P (2000) Calcineurin: form and function. Physiol Rev 80:1483–1521. https://doi.org/10.1152/physrev.2000.80.4.1483
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476. https://doi.org/10.1056/NEJMoa050516
Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2014) Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 5:682. https://doi.org/10.3389/fimmu.2014.00682
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, De Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, Group CS (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367:1519–1528. https://doi.org/10.1056/NEJMoa1203572
Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Study AI (2014) A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(1485–1493):e1482. https://doi.org/10.1016/j.cgh.2014.01.029
Sandborn WJ, Feagan BG, Wolf DC, D’haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A (2016) Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374:1754–1762. https://doi.org/10.1056/NEJMoa1513248
Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W (2019) Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology 156:946-957.e918. https://doi.org/10.1053/j.gastro.2018.11.035
Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J (2020a) Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohns Colitis 14:1202–1213. https://doi.org/10.1093/ecco-jcc/jjaa049
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J (2020b) Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology 158:550–561. https://doi.org/10.1053/j.gastro.2019.10.035
Sands BE, Sandborn WJ, Panaccione R, Obrien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, Group US (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214. https://doi.org/10.1056/NEJMoa1900750
Santos-Antunes J, Nunes AC, Lopes S, Macedo G (2016) The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study. Inflamm Bowel Dis 22:1101–1106. https://doi.org/10.1097/MIB.0000000000000697
Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3:390–407. https://doi.org/10.1038/ncpgasthep0528
Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594. https://doi.org/10.1053/j.gastro.2007.11.059
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, Mcdonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Irving PM, Barrett JC, Mcgovern D, Goodhand JR, Anderson CA, Ahmad T (2020) HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology 158:189–199. https://doi.org/10.1053/j.gastro.2019.09.041
Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A, Group CDPCsDS (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129:807–818. https://doi.org/10.1053/j.gastro.2005.06.064
Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J (2009) Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis 15:734–741. https://doi.org/10.1002/ibd.20828
Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, Prince J, Kumar A, Sauer C, Zwick ME, Satten GA, Kostic AD, Mulle JG, Xavier RJ, Kugathasan S (2016) Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med 8:75. https://doi.org/10.1186/s13073-016-0331-y
Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G 3rd, Tam S, Sague S, Wang D, Brigham-Burke M, Dalmonte P, Emmell E, Pikounis B, Bugelski PJ, Zhou H, Scallon BJ, Giles-Komar J (2010) Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2:428–439. https://doi.org/10.4161/mabs.12304
Shoda R, Matsueda K, Yamato S, Umeda N (1996) Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 63:741–745. https://doi.org/10.1093/ajcn/63.5.741
Singh S, Proudfoot J, Xu R, Sandborn WJ (2018) Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol 113:883–889. https://doi.org/10.1038/s41395-018-0104-x
Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH (2018) Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther 192:100–111. https://doi.org/10.1016/j.pharmthera.2018.07.003
Sonnenberg A (1988) Geographic and temporal variations of sugar and margarine consumption in relation to Crohn’s disease. Digestion 41:161–171. https://doi.org/10.1159/000199769
Stolfi C, De Simone V, Pallone F, Monteleone G (2013) Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci 14:17972–17985. https://doi.org/10.3390/ijms140917972
Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant 2012:230386. https://doi.org/10.1155/2012/230386
Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, Cai Q, Zhao DB (2013) Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 14:1691–1700. https://doi.org/10.2217/pgs.13.146
Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B (1988) Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29:990–996. https://doi.org/10.1136/gut.29.7.990
Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W (2017) Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390:135–144. https://doi.org/10.1016/S0140-6736(17)30930-3
Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, Ferrante M, Breynaert C (2019a) Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn’s disease. Aliment Pharmacol Ther 49:572–581. https://doi.org/10.1111/apt.15126
Verstockt S, Verstockt B, Vermeire S (2019b) Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opin Ther Targets 23:943–954. https://doi.org/10.1080/14728222.2019.1677608
West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F, Investigators OIC (2017) Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23:579–589. https://doi.org/10.1038/nm.4307
Wong U, Cross RK (2017) Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 13:1039–1046. https://doi.org/10.1080/17425255.2017.1377180
Yamazaki K, Umeno J, Takahashi A, Hirano A, Johnson TA, Kumasaka N, Morizono T, Hosono N, Kawaguchi T, Takazoe M, Yamada T, Suzuki Y, Tanaka H, Motoya S, Hosokawa M, Arimura Y, Shinomura Y, Matsui T, Matsumoto T, Iida M, Tsunoda T, Nakamura Y, Kamatani N, Kubo M (2013) A genome-wide association study identifies 2 susceptibility Loci for Crohn’s disease in a Japanese population. Gastroenterology 144:781–788. https://doi.org/10.1053/j.gastro.2012.12.021
Yang SK, Hong M, Zhao W, Jung Y, Tayebi N, Ye BD, Kim KJ, Park SH, Lee I, Shin HD, Cheong HS, Kim LH, Kim HJ, Jung SA, Kang D, Youn HS, Liu J, Song K (2013) Genome-wide association study of ulcerative colitis in Koreans suggests extensive overlapping of genetic susceptibility with Caucasians. Inflamm Bowel Dis 19:954–966. https://doi.org/10.1097/MIB.0b013e3182802ab6
Yang SK, Hong M, Zhao W, Jung Y, Baek J, Tayebi N, Kim KM, Ye BD, Kim KJ, Park SH, Lee I, Lee EJ, Kim WH, Cheon JH, Kim YH, Jang BI, Kim HS, Choi JH, Koo JS, Lee JH, Jung SA, Lee YJ, Jang JY, Shin HD, Kang D, Youn HS, Liu J, Song K (2014) Genome-wide association study of Crohn’s disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 63:80–87. https://doi.org/10.1136/gutjnl-2013-305193
Yilmaz B, Juillerat P, Úyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G, Wiest R, Stelling J, Macpherson AJ, Investigators SIC (2019) Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med 25:323–336. https://doi.org/10.1038/s41591-018-0308-z
Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T, Group AS (2015) Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology 149:1775-1783.e1772. https://doi.org/10.1053/j.gastro.2015.08.044
Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933. https://doi.org/10.1056/NEJMoa054693
Zhang YZ, Li YY (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20:91–99. https://doi.org/10.3748/wjg.v20.i1.91
Acknowledgements
This work was supported by the Chung-Ang University Graduate Research Scholarship in 2019 (W.-H. Kim) and National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT, no. NRF-2020R1F1A1075489; C. H. Choi).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, KU., Kim, J., Kim, WH. et al. Treatments of inflammatory bowel disease toward personalized medicine. Arch. Pharm. Res. 44, 293–309 (2021). https://doi.org/10.1007/s12272-021-01318-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01318-6